Alzheimer’s Disease vs Multiple Sclerosis Drug Development: Similarities, Differences & New Perspectives
While Alzheimer’s Disease and Multiple Sclerosis are both neurological disorders they differ in disease mechanisms, trial objectives, patient populations, and outcomes used in clinical trials. Lessons shared in the drug development journeys of both diseases can propel novel approaches leading to more effective and successful clinical trials in the quest for new treatments and better patient outcomes.
Learning from the experience of Multiple Sclerosis trials, Alzheimer’s trials can benefit from improved trial design, patient stratifications, outcome assessments, and incorporation of innovative methodologies.
In this webinar, distinguished physicians, experienced scientists, and clinical development experts, from Multiple Sclerosis and Alzheimer’s will discuss the main development challenges and how they were overcome in each respectively. This is the first-ever webinar discussing the AD vs. MS world perspective with top clinical research experts and disease area specialists.